US FDA accepts Novo Nordisk's NDA submission for oral semaglutide 25 mg for treatment of obesity
Novo Nordisk, a leading global healthcare company, announced that the US Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy (semaglutide) for chronic …